- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
Biogen is a drug manufacturers - general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $157.78 – a decrease of 1.77% over the previous week. Biogen employs 7,570 staff and has a trailing 12-month revenue of around $9.6 billion.
What's in this guide?
Our top picks for where to buy Biogen stock
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Complimentary access to a financial planner
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
How to buy Biogen stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BIIB. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Biogen stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Biogen stock price (NASDAQ: BIIB)
Use our graph to track the performance of BIIB stocks over time.Biogen shares at a glance
Latest market close | $157.78 |
---|---|
52-week range | $153.62 - $268.30 |
50-day moving average | $177.24 |
200-day moving average | $205.74 |
Wall St. target price | $254.26 |
PE ratio | 14.5366 |
Dividend yield | N/A |
Earnings per share (TTM) | $11.07 |
Is it a good time to buy Biogen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biogen price performance over time
Historical closes compared with the close of $160.92 from 2024-12-04
1 week (2024-12-03) | 0.04% |
---|---|
1 month (2024-11-11) | -6.46% |
3 months (2024-09-10) | -19.80% |
6 months (2024-06-10) | -28.79% |
1 year (2023-12-08) | -32.75% |
---|---|
2 years (2022-12-09) | -43.61% |
3 years (2021-12-10) | 232.62 |
5 years (2019-12-10) | 297.2 |
Is Biogen stock undervalued or overvalued?
Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biogen's P/E ratio
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Biogen shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biogen's PEG ratio
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biogen's EBITDA
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 billion.
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
Biogen financials
Revenue TTM | $9.6 billion |
---|---|
Operating margin TTM | 20.74% |
Gross profit TTM | $7.9 billion |
Return on assets TTM | 4.99% |
Return on equity TTM | 10.47% |
Profit margin | 16.81% |
Book value | $112.28 |
Market Capitalization | $23.4 billion |
TTM: trailing 12 months
Biogen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Biogen's total ESG risk score
Total ESG risk: 22.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 22.95 (as at 12/31/2018) is pretty good – landing it in it in the 34th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Biogen's environmental score
Environmental score: 1.02/100
Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Biogen's social score
Social score: 13.48/100
Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Biogen's governance score
Governance score: 7.45/100
Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Biogen's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Biogen Inc was last rated for ESG on: 2019-01-01.
Total ESG score | 22.95 |
---|---|
Total ESG percentile | 33.82 |
Environmental score | 1.02 |
Environmental score percentile | 2 |
Social score | 13.48 |
Social score percentile | 2 |
Governance score | 7.45 |
Governance score percentile | 2 |
Level of controversy | 2 |
Biogen share dividends
We're not expecting Biogen to pay a dividend over the next 12 months.
Have Biogen's shares ever split?
Biogen's shares were split on a 3:1 basis on 17 January 2001 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.
Biogen share price volatility
Over the last 12 months, Biogen's shares have ranged in value from as little as $153.62 up to $268.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is -0.061. This would suggest that Biogen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biogen has bucked the trend.
Biogen overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc. ; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.
Frequently asked questions
nullWhat percentage of Biogen is owned by insiders or institutions?
Currently 0.153% of Biogen shares are held by insiders and 92.965% by institutions. How many people work for Biogen?
Latest data suggests 7,570 work at Biogen. When does the fiscal year end for Biogen?
Biogen's fiscal year ends in December. Where is Biogen based?
Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142 What is Biogen's ISIN number?
Biogen's international securities identification number is: US09062X1037 What is Biogen's CUSIP number?
Biogen's Committee on Uniform Securities Identification Procedures number is: 449370105
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask a question